IRS-4 Inhibitors

IRS-4 inhibitors encompass a range of chemicals that either directly or indirectly modulate the activity of Insulin Receptor Substrate 4 (IRS-4) by targeting specific signaling pathways. Wortmannin and LY294002 directly inhibit IRS-4 by targeting the PI3K pathway, disrupting downstream signaling cascades and attenuating phosphorylation. Rapamycin indirectly influences IRS-4 through mTOR inhibition, altering phosphorylation and activation. MK-2206 directly inhibits IRS-4 by targeting the AKT pathway, disrupting downstream signaling and interfering with IRS-4 activation.

BAY-61-3606 indirectly influences IRS-4 through Syk inhibition, impacting the JAK/STAT pathway. U0126 and SB202190 directly inhibit IRS-4 by targeting the MAPK/ERK and p38 MAPK pathways, respectively. BMS-345541 indirectly modulates IRS-4 through IKK inhibition, affecting the NF-κB pathway. TGX-221 directly inhibits IRS-4 by targeting the PI3K pathway, disrupting downstream signaling cascades. JNK Inhibitor VIII directly influences IRS-4 by inhibiting the JNK pathway. AG-1024 directly inhibits IRS-4 by targeting the IGF-1R pathway, disrupting downstream signaling and interfering with IRS-4 activation. BAY 11-7082 indirectly influences IRS-4 through NF-κB inhibition, altering phosphorylation and activation. These inhibitors provide valuable tools for dissecting the intricate signaling networks involving IRS-4, offering insights into its regulatory mechanisms.